Jun 27, 2021
3 min read
23andMe: genetics goes public
On June 17, 23andMe, which pioneered personalized medicine and at-home genetic testing kits 15 years ago, went public through a merger with a Richard Branson SPAC under the ME ticker and saw its share price rise by 21%, reflecting the market’s interest in the potential of genetic analysis.
Fifteen years of offering saliva tests (spit kits) to the general public at a price of around $99 has allowed the company…
